Our objective is to review emerging technologies intended for the treatment of depression and other neuropsychiatric disorders.
Methods
These technologies include repetitive transcranial magnetic stimulation (rTMS), magnetic seizure therapy (MST), vagus nerve stimulation (VNS), deep brain stimulation (DBS), cortical brain stimulation (CBS), and quantitative electroencephalography (QEEG).
Results
The rationale for these technologies, their mechanisms of action, and how they are used in clinical practice are described. rTMS and VNS are effective for treatment-resistant depression. DBS is effective for resistant obsessive-compulsive disorder. QEEG can help predict a patient's response to an antidepressant. All of these technologies continue to be investigated in treatment studies.
Conclusions
As these and other emerging technologies for depression and other neuropsychiatric disorders are development and applied, psychiatrists should understand the rationale for these modalities, how they work, and how they can be used in clinical practice.
NestlerEJ, BarrotM, DiLeoneRJ, . Neurobiology of depression. Neuron. 2002;34:13–25.
2.
ResslerKJ, MaybergHS.Targeting abnormal neural circuits in mood and anxiety disorders: from the laboratory to the clinic. Nat Neurosci. 2007;10:1116–1124.
SurguladzeS, KeedwellP, PhillipsM.Neural systems underlying affective disorders. Advances in Psychiatric Treatment. 2003;9:446–455.
5.
ChenCH, RidlerK, SucklingJ, . Brain imaging correlates of depressive symptom severity and predictors of symptom improvement after antidepressant treatment. Biol Psychiatry. 2007;62:407–414.
6.
MaybergHS.Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull. 2003;65:193–207.
7.
BrodyAL, SaxenaS, StoesselP, . Regional brain metabolic changes in patients with major depression treated with either paroxetine or interpersonal therapy: preliminary findings. Arch Gen Psychiatry. 2001;58:631–640.
8.
GoldappleK, SegalZ, GarsonC, . Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry. 2004;61:34–41.
9.
BenedettiF, MaybergHS, WagerTD, . Neurobiological mechanisms of the placebo effect. J Neurosci. 2005;25:10390–10402.
10.
MaybergHS, SilvaJA, BrannanSK, . The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728–737.
11.
PressmanJD.Last resort: psychosurgery and the limits of medicine.Cambridge, United Kingdom: Cambridge University Press; 1998.
12.
ValensteinES.Great and desperate cures: the rise and decline of psychosurgery and other radical treatments for mental illness.New York, NY: Basic Books; 1986.
13.
BinderDK, IskandarBJ.Modern neurosurgery for psychiatric disorders. Neurosurgery. 2000;47:9–23.
14.
EljamelMS.Ablative neurosurgery for mental disorders: is there still a role in the 21st century?A personal perspective. Neurosurg Focus. 2008;25:E4.
15.
SteeleJD, ChristmasD, EljamelMS, . Anterior cingulotomy for major depression: Clinical outcome and relationship to lesion characteristics. Biol Psychiatry. 2008;63:670–677.
16.
GreenbergBD, PriceLH, RauchSL, . Neurosurgery for intractable obsessive-compulsive disorder and depression: critical issues. Neurosurg Clin N Am. 2003;14:199–212.
17.
CoweyA.The Ferrier Lecture 2004: what can transcranial magnetic stimulation tell us about how the brain works?Philos Trans R Soc Lond B Biol Sci.2005;360:1185–1205.
18.
LooCK, McFarquharTF, MitchellPB.A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. Int J Neuropsycho-pharmacol. 2008;11:131–147.
19.
XiaG, GajwaniP, MuzinaDJ, . Treatment-emergent mania in unipolar and bipolar depression: focus on repetitive transcranial magnetic stimulation. Int J Neuropsychopharmacol. 2008;11:119–130.
20.
VanderhasseltMA, De RaedtR, BaekenC, . The influence of rTMS over the left dorsolateral prefrontal cortex on Stroop task performance. Exp Brain Res. 2006;169:279–282.
21.
KozelAF, GeorgeMS.Meta-analysis of left prefrontal repetitive transcranial magnetic stimulation (rTMS) to treat depression. J Psychiatr Pract. 2002;8:270–275.
22.
RogersMA, KasaiK, KojiM, . Executive and prefrontal dysfunction in unipolar depression: a review of neuropsychological and imaging evidence. Neurosci Res. 2004;50:1–11.
23.
GeorgeMS, LisanbySH, AveryD, . Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67:507–516.
24.
GrossM, NakamuraL, Pascual-LeoneA, . Has repetitive transcranial magnetic stimulation (rTMS) treatment for depression improved? A systematic review and meta-analysis comparing the recent vs. the earlier rTMS studies. Acta Psychiatr Scand. 2007;116:165–173.
25.
LamRW, ChanP, Wilkins-HoM, . Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis. Can J Psychiatry. 2008;53:621–631.
26.
FitzgeraldPB, HoyK, McQueenS, . Priming stimulation enhances the effectiveness of low-frequency right prefrontal cortex transcranial magnetic stimulation in major depression. J Clin Psychopharmacol. 2008;28:52–58.
27.
MichaelN, ErfurthA.Treatment of bipolar mania with right prefrontal rapid transcranial magnetic stimulation. J Affect Disord. 2004;78:253–257.
28.
GrisaruN, ChudakovB, YaroslavskyY, . Transcranial magnetic stimulation in mania: a controlled study. Am J Psychiatry. 1998;155:1608–1610.
29.
GrimmS, BeckJ, SchuepbachD, HellD, . Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biol Psychiatry. 2008;63:369–376.
30.
O'ReardonJP, SolvasonHB, JanicakPG, . Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62:1208–1216.
31.
ErantiS, MoggA, PluckG, . A randomized controlled trial with 6-month follow-up of repetitive transcranial magnetic stimulation and electroconvulsive therapy for severe depression. Am J Psychiatry. 2007;164:73–81.
32.
McLoughlinDM, MoggA, ErantiS, . The clinical effectiveness and cost of repetitive transcranial magnetic stimulation versus electroconvulsive therapy in severe depression: a multicentre pragmatic randomised controlled trial and economic analysis. Health Technol Assess. 2007;11:1–54.
33.
Demirtas-TatlidedeA, Mechanic-HamiltonD, PressDZ, . An open-label prospective study of repetitive transcranial magnetic stimulation (rTMS) in the long-term treatment of refractory depression: reproducibility and duration of the antidepressant effect in medication-free patients. J Clin Psychiatry. 2008;69:930–934.
34.
JanicakPG, NahasZ, LisanbySH, . Durability of clinical benefit with transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant major depression: assessment of relapse during a 6-month multisite open-label study. Brain Stimul. 2010;3:187–199.
35.
PigotM, LooC, SachdevP.Repetitive transcranial magnetic stimulation as treatment for anxiety disorders. Expert Rev Neurother. 2008;8:1449–1455.
36.
AlemanA, SommerIE, KahnRS.Efficacy of slow repetitive transcranial magnetic stimulation in the treatment of resistant auditory hallucinations in schizophrenia: a meta-analysis. J Clin Psychiatry. 2007;68:416–421.
37.
TranulisC, SepehryAA, GalinowskiA, . Should we treat auditory hallucinations with repetitive transcranial magnetic stimulation? A metaanalysis. Can J Psychiatry. 2008;53:577–586.
38.
MállyJ, DinyaE.Recovery of motor disability and spasticity in post-stroke after repetitive transcranial magnetic stimulation (rTMS). Brain Res Bull. 2008;76:388–395.
39.
MansurCG, FregniF, BoggioPS, . A sham stimulation-controlled trial of rTMS of the unaffected hemisphere in stroke patients. Neurology. 2005;64:1802–1804.
40.
NowakDA, GrefkesC, DafotakisM, . Effects of low-frequency repetitive transcranial magnetic stimulation of the contralesional primary motor cortex on movement kinematics and neural activity in subcortical stroke. Arch Neurol. 2008;65:741–747.
41.
PlewniaC, ReimoldM, NajibA, . Moderate therapeutic efficacy of positron emission tomography-navigated repetitive transcranial magnetic stimulation for chronic tinnitus: a randomised controlled pilot study. J Neurol Neurosurg Psychiatry. 2007;78:152–156.
42.
PridmoreS, KleinjungT, LangguthB, . Transcranial magnetic stimulation: potential treatment for tinnitus?Psychiatry Clin Neurosci. 2006;60:133–138.
43.
LeoRJ, LatifT.Repetitive transcranial magnetic stimulation (rTMS) in experimentally induced and chronic neuropathic pain: a review. J Pain. 2007;8: 453–459.
44.
BrighinaF, PiazzaA, VitelloG, . rTMS of the prefrontal cortex in the treatment of chronic migraine: a pilot study. J Neurol Sci. 2004;227:67–71.
45.
Alonso-AlonsoM, Pascual-LeoneA.The right brain hypothesis for obesity. JAMA. 2007;297:1819–1822.
46.
BystritskyA, KerwinL, FeusnerJ.A pilot study of cranial electrotherapy stimulation for generalized anxiety disorder. J Clin Psychiatry. 2008;69:412–417.
47.
BoggioPS, RigonattiSP, RibeiroRB, . A randomized, double-blind clinical trial on the efficacy of cortical direct current stimulation for the treatment of major depression. Int J Neuropsychopharmacol. 2008;11:249–254.
48.
GeorgeMS, NahasZ, BorckardtJJ, . Brain stimulation for the treatment of psychiatric disorders. Curr Opin Psychiatry. 2007;20:250–254.
49.
LisanbySH, LuberB, SchlaepferTE, . Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003;28:1852–1865.
50.
SpellmanT, McClintockSM, TerraceH, . Differential effects of high-dose magnetic seizure therapy and electroconvulsive shock on cognitive function. Biol Psychiatry. 2008;63:1163–1170.
51.
GeorgeMS, SackeimHA, RushAJ, . Vagus nerve stimulation: a new tool for brain research and therapy. Biol Psychiatry. 2000;47:287–295.
52.
ZagonA.Does the vagus nerve mediate the sixth sense? Trends Neurosci. 2001;24:671–673.
53.
LanskaDJ.J.L. Corning and vagal nerve stimulation for seizures in the 1880s. Neurology. 2002;58:452–459.
54.
ZabaraJ.Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia. 1992;33:1005–1012.
55.
VonckK, Van LaereK, DedeurwaerdereS, . The mechanism of action of vagus nerve stimulation for refractory epilepsy: the current status. J Clin Neurophysiol. 2001;18:394–401.
56.
StancakA, KunaM, Srinivasan, . Kapalabhati— yogic cleansing exercise. II. EEG topography analysis. Homeost Health Dis. 1991;3:182–189.
GeorgeMS, RushAJ, SackeimHA, . Vagus nerve stimulation (VNS): utility in neuropsychiatric disorders. Int J Neuropsychopharmacol. 2003;6:73–83.
63.
KrahlSE, SenanayakeSS, PekaryAE, . Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J Psychiatr Res. 2004;38:237–240.
64.
RushAJ, GeorgeMS, SackeimHA, . Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47:276–286.
65.
SackeimHA, RushAJ, GeorgeMS, . Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25:713–728.
66.
MarangellLB, RushAJ, GeorgeMS, . Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes. Biol Psychiatry. 2002;51:280–287.
67.
NahasZ, MarangellLB, HusainMM, . Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66:1097–1104.
68.
DunnerDL, RushAJ, RussellJM, . Prospective long-term multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67:688–695.
69.
RushAJ, MarangellLB, SackeimHA, . Vagus nerve stimulation for treatment-resistant depression: a randomized controlled acute phase trial. Biol Psychiatry. 2005;58:347–354.
70.
RushAJ, SackeimHA, MarangellLB, . Effects of 12 months of vagus nerve stimulation in treatmentresistant depression: a naturalistic study. Biol Psychiatry. 2005;58:355–363.
71.
GeorgeMS, RushAJ, MarangellLB, . A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58:364–373.
72.
NierenbergAA, AlpertJE, Gardner-SchusterEE, . Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depression. Biol Psychiatry. 2008;64:455–460.
RushAJ, FavaM, WisniewskiSR, , and the STAR*D Study Team. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25:119–142.
75.
TrivediMH, RushAJ, WisniewskiSR, , and the STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 2006;163:28–40.
76.
RushAJ, TrivediMH, WisniewskiSR, , and the STAR*D Study Team. Bupropion-SR, sertraline, or venla-faxine-XR after failure of SSRIs for depression. N Engl J Med. 2006;354:1231–1242.
77.
TrivediMH, FavaM, WisniewskiSR, , and the STAR*D Study Team. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–1252.
78.
FavaM, RushAJ, WisniewskiSR, , and the STAR*D Study Team. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry. 2006;163:1161–1172.
79.
NierenbergAA, FavaM, TrivediMH, , and the STAR*D Study Team. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163:1519–1530.
80.
McGrathPJ, StewartJW, FavaM, , and the STAR*D Study Team. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry. 2006;163:1531–1541.
81.
MarangellLB, SuppesT, ZboyanHA, . A 1-year pilot study of vagus nerve stimulation in treatmentresistant rapid-cycling bipolar disorder. J Clin Psychiatry. 2008;69:183–189.
82.
GeorgeMS, WardHEJr, NinanPT, . A pilot study of vagus nerve stimulation (VNS) for treatmentresistant anxiety disorders. Brain Stimul. 2008;1:112–121.
83.
SackeimHA, KeilpJG, RushAJ, . The effects of vagus nerve stimulation on cognitive performance in patients with treatment-resistant depression. Neuropsychiatry Neuropsychol Behav Neurol. 2001;14:53–62.
84.
SjögrenMJ, HellströmPT, JonssonMA, . Cognition-enhancing effect of vagus nerve stimulation in patients with Alzheimer's disease: a pilot study. J Clin Psychiatry. 2002;63:972–980.
85.
MerrillCA, JonssonMA, MinthonL, . Vagus nerve stimulation in patients with Alzheimer's disease: additional follow-up results of a pilot study through 1 year. J Clin Psychiatry. 2006;67:1171–1178.
86.
MultonS, SchoenenJ.Pain control by vagus nerve stimulation: from animal to man… and back. Acta Neurol Belg. 2005;105:62–67.
87.
LenaertsME, OommenKJ, CouchJR, . Can vagus nerve stimulation help migraine?Cephalalgia. 2008;28:392–395.
BerthoudHR.The vagus nerve, food intake, and obesity. Regul Pept. 2008;149:15–25.
90.
BurneoJG, FaughtE, KnowltonR, . Weight loss associated with vagus nerve stimulation. Neurology. 2002;59:463–464.
91.
PardoJV, SheikhSA, KuskowskiMA, . Weight loss during chronic cervical vagus nerve stimulation in depressed patients with obesity: an observation. Int J Obes (Lond). 2007;31:1756–1759.
92.
SobockiJ, KrólczykG, HermanRM, . Influence of vagal nerve stimulation on food intake and body weight: results of experimental studies. J Physiol Pharmacol. 2005;56:(suppl 6)27–33.
93.
RoslinM, KurianM.The use of electrical stimulation of the vagus nerve to treat morbid obesity. Epilepsy Behav. 2001;2:(suppl)S11–S16.
94.
PereiraEA, GreenAL, NandiD, . Deep brain stimulation: indications and evidence. Expert Rev Med Devices. 2007;4:591–603.
95.
PilitsisJG, MetmanLV, ToleikisJR, . Factors involved in long-term efficacy of deep brain stimulation of the thalamus for essential tremor. J Neurosurg. 2008;109:640–646.
96.
MoroE, LangAE.Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother. 2006;6:1695–1705.
97.
JohnsonMD, MiocinovicS, McIntyreCC, . Mechanisms and targets of deep brain stimulation in movement disorders. Neurotherapeutics. 2008;5:294–308.
98.
HalpernCH, SamadaniU, LittB, . Deep brain stimulation for epilepsy. Neurotherapeutics. 2008;5: 59–67.
99.
DuncanGH, BushnellMC, MarchandS.Deep brain stimulation: a review of basic research and clinical studies. Pain. 1991;45:49–59.
100.
LevyRM, LambS, AdamsJE.Treatment of chronic pain by deep brain stimulation: long term follow-up and review of the literature. Neurosurgery. 1987;21:885–893.
101.
HalpernCH, WolfJA, BaleTL, . Deep brain stimulation in the treatment of obesity. J Neurosurg. 2008;109:625–634.
102.
SalehC, OkunMS.Clinical review of deep brain stimulation and its effects on limbic basal ganglia circuitry. Front Biosci. 2008;13:5708–5731.
103.
LipsmanN, NeimatJS, LozanoAM.Deep brain stimulation for treatment-refractory obsessive-compulsive disorder: the search for a valid target. Neurosurgery. 2007;61:1–13.
104.
van LaereK, NuttinB, GabrielsL, . Metabolic imaging of anterior capsular stimulation in refractory obsessive-compulsive disorder: a key role for the subgenual anterior cingulate and ventral striatum. J Nucl Med. 2006;47:740–747.
105.
AbelsonJL, CurtisGC, SagherO, . Deep brain stimulation for refractory obsessive-compulsive disorder. Biol Psychiatry. 2005;57:510–516.
106.
GreenbergBD, MaloneDA, FriehsGM, . Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology. 2006;31:2384–2393.
107.
NuttinBJ, GabriëlsLA, CosynsPR, . Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery. 2003;52:1263–1274.
108.
AgidY, BuzsákiG, DiamondDM, . How can drug discovery for psychiatric disorders be improved?Nat Rev Drug Discov. 2007;6:189–201.
109.
MaybergHS, LozanoAM, VoonV, . Deep brain stimulation for treatment-resistant depression. Neuron. 2005;45:651–660.
110.
LozanoAM, MaybergHS, GiacobbeP, . Sub-callousal cingulate gyrus deep brain stimulation for treatment-resistant depression. Biol Psychiatry. 2008; 64:461–467.
111.
GreenbergB, FriehsG, CarpenterL, . Deep brain stimulation: clinical findings in intractable depression and OCD (Abstract). Neuropsychopharmacology. 2004;29:S32.
112.
MaloneDA, DoughertyDD, RezaiAR, . Deep brain stimulation of the ventral capsule/ventral striatum for treatment-resistant depression. Biol Psychiatry. 2009;65:267–275.
113.
BewernickBH, HurlemannR, MatuschA, . Nucleus accumbens deep brain stimulation decreases ratings of depression and anxiety in treatment-resistant depression. Biol Psychiatry. 2010;67:110–116.
114.
HauptmanJS, DeSallesAA, EspinozaR, . Potential surgical targets for deep brain stimulation in treatment-resistant depression. Neurosurg Focus. 2008;25:E3.
115.
FriedlandDR, GagglW, Runge-SamuelsonC, . Feasibility of auditory cortical stimulation for the treatment of tinnitus. Otol Neurotol. 2007;28:1005–1012.
116.
HarveyRL, NudoRJ.Cortical brain stimulation: a potential therapeutic agent for upper limb motor recovery following stroke. Top Stroke Rehabil. 2007;14:54–67.
117.
DoughertyDD, ThaseME, HowlandRH, . Feasibility study of an implantable cortical stimulation system for patients with major depressive disorder. Biol Psychiatry. 2008;63:294S–295S.
118.
HowlandRH, ThaseME, EvansK, . Feasibility study of an implantable cortical stimulation system for patients with major depressive disorder. Paper presented at: American Psychiatric Association Annual Meeting; May 3-8, 2008; Washington, DC.
119.
KopellBH, KondziolkaD, DoughertyDD, . Feasibility study of the safety and effectiveness of an implantable cortical stimulation system for subjects with major depression (Abstract 863). Neurosurgery. 2007;61:215.
GrillWM.Safety considerations for deep brain stimulation: review and analysis. Expert Rev Med Devices. 2005;2:409–420.
122.
HamaniC, LozanoAM.Hardware-related complications of deep brain stimulation: a review of the published literature. Stereotact Funct Neurosurg. 2006;84:248–251.
123.
FieldsJA, TrösterAI. Cognitive outcomes after deep brain stimulation for Parkinson's disease: a review of initial studies and recommendations for future research. Brain Cogn. 2000;42:268–293.
124.
WoodsSP, FieldsJA, TrösterAI. Neuropsychological sequelae of subthalamic nucleus deep brain stimulation in Parkinson's disease: a critical review. Neuropsychol Rev.2002;12:111–126.
125.
DalyDD, PedleyTA, eds. Current practice of clinical electroencephalography, 2nd ed.New York, NY: Raven Press; 1990.
126.
LeuchterAF, CookIA, UijtdehaageSH, . Brain structure and function, and the outcomes of treatment for depression. J Clin Psychiatry. 1997;58:(suppl 16)22–31.
127.
LeuchterAF, CookIA, LufkinRB, . Cordance: a new method for assessment of cerebral perfusion and metabolism using quantitative electroencephalography. Neuroimage. 1994;1:208–219.
128.
LeuchterAF, UijtdehaageSH, CookIA, . Relationship between brain electrical activity and cortical perfusion in normal subjects. Psychiatry Res. 1999;90:125–140.
129.
DrevetsWC, GaddeKM, KrishnanKRR.Neuroimaging studies of mood disorders. In: CharneyDS, NestlerEJ, eds. Neurobiology of mental illness, 2nd ed.New York, NY: Oxford University Press; 2004:461–490.
130.
BruderGE, StewartJW, TenkeCE, . Electroen cephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant. Biol Psychiatry. 2001;49:416–425.
131.
PizzagalliD, Pascual-MarquiRD, NitschkeJB, . Anterior cingulate activity as a predictor of degree of treatment response in major depression: evidence from brain electrical tomography analysis. Am J Psychiatry. 2001;158:405–415.
132.
KnottVJ, TelnerJI, LapierreYD, . Quantitative EEG in the prediction of antidepressant response to imipramine. J Affect Disord. 1996;39:175–184.
133.
KnottV, MahoneyC, KennedyS, . EEG correlates of acute and chronic paroxetine treatment in depression. J Affect Disord. 2002;69:241–249.
134.
UlrichG, HaugHJ, FähndrichE.Acute versus chronic EEG effects of maprotiline-and in clomipramine-treated depressive inpatients and the prediction of therapeutic outcome. J Affect Disord. 1994;32:213–217.
135.
CookIA, LeuchterAF, MorganM, . Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120–131.
136.
LeuchterAF, CookIA, WitteEA, . Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122–129.
137.
HunterAM, LeuchterAF, MorganML, . Changes in brain function (quantitative EEG cordance) during placebo lead-in and treatment outcomes in clinical trials for major depression. Am J Psychiatry. 2006;163:1426–1432.
138.
HunterAM, LeuchterAF, MorganML, . Neurophysiologic correlates of side effects in normal subjects randomized to venlafaxine or placebo. Neuropsychopharmacology. 2005;30:792–799.
139.
CookIA, LeuchterAF, MorganML, . Changes in prefrontal activity characterize clinical response in SSRI nonresponders: a pilot study. J Psychiatr Res. 2005;39:461–466.
140.
CookIA, LeuchterAF, GreenwaldSD, . QEEG cordance predicts treatment response to reboxetine in major depression. Paper presented at: American Psychiatric Association Annual Meeting; May 17-22, 2003; San Francisco, CA.
141.
LeuchterAF, KofolT, GreenwaldSD, . Source localization of anterior cingulate activity: comparison of 4 vs. 24 channel EEG techniques. Paper presented at: American Psychiatric Association Annual Meeting; May 21-26, 2005; Atlanta, GA.
142.
IosifescuDV, GreenwaldS, SmithCP, . Frontal EEG at 1 week predicts clinical response to SSRI treatment in major depressive disorder. Paper presented at: American Psychiatric Association Annual Meeting; May 20-25, 2006; Toronto, Canada.
143.
PolandRE, GreenwaldS, SmithCP, . Frontal EEG at 1 week predicts response to treatment with citalopram in MDD. Paper presented at: American Psychiatric Association Annual Meeting; May 20-25, 2006; Toronto, Canada.
144.
IosifescuDV, GreenwaldS, DevlinP, . Pretreatment frontal EEG and changes in suicidal ideation during SSRI treatment in major depressive disorder. Acta Psychiatr Scand. 2008;117:271–276.
145.
LeuchterAF, CookIA, MarangellLB, . Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res. 2009;169:124–131.
146.
LeuchterAF, CookIA, GilmerWS, . Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder. Psychiatry Res. 2009;169:132–138.
147.
HowlandRH.Therapeutic armamentarium for treating depression. Postgrad Med. 2010;122:66–93.
148.
RushAJ, TrivediMH, WisniewskiSR, . Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;63:1905–1917.
